Analyst Price Targets — RMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 30, 2026 12:54 pm | Craig Wong-Pan | RBC Capital | $314.00 | $254.08 | TheFly | ResMed price target raised to $314 from $311 at RBC Capital |
| January 30, 2026 12:40 pm | — | Stifel Nicolaus | $265.00 | $257.61 | TheFly | ResMed price target raised to $265 from $260 at Stifel |
| January 30, 2026 12:40 pm | Brett Fishbin | KeyBanc | $302.00 | $257.61 | TheFly | ResMed price target raised to $302 from $299 at KeyBanc |
| January 30, 2026 12:25 pm | — | Robert W. Baird | $281.00 | $257.61 | TheFly | ResMed price target raised to $281 from $275 at Baird |
| January 30, 2026 12:04 pm | — | Piper Sandler | $275.00 | $257.61 | TheFly | ResMed price target raised to $275 from $270 at Piper Sandler |
| December 18, 2025 9:02 am | Jonathan Block | Stifel Nicolaus | $260.00 | $245.94 | StreetInsider | ResMed (RMD) PT Lowered to $260 at Stifel |
| December 16, 2025 10:19 am | — | Robert W. Baird | $275.00 | $253.07 | TheFly | ResMed downgraded to Neutral from Outperform at Baird |
| December 12, 2025 2:38 pm | Marcus Curley | UBS | $345.00 | $251.38 | StreetInsider | ResMed (RMD) PT Raised to $345 at UBS |
| November 3, 2025 12:08 pm | — | Robert W. Baird | $300.00 | $246.88 | TheFly | ResMed price target lowered to $300 from $320 at Baird |
| October 31, 2025 1:01 pm | Brett Fishbin | KeyBanc | $299.00 | $244.12 | TheFly | ResMed price target raised to $299 from $298 at KeyBanc |
Latest News for RMD
Aster Capital Management DIFC Ltd purchased a new position in shares of ResMed Inc. (NYSE: RMD) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,252 shares of the medical equipment provider's stock, valued at approximately $616,000. Other institutional
Empirical Asset Management LLC acquired a new stake in ResMed Inc. (NYSE: RMD) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,066 shares of the medical equipment provider's stock, valued at approximately $839,000. Several other institutional investors have also made
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maintaining solid cash flow and margin, has a low-debt capital structure, and is fairly valued.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, EAT, FTI and RMD hold promise.
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed's U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.